Microdoses of Weight Loss Drugs Show Potential to Reverse Ageing

New research suggests that microdoses of weight loss drugs like Ozempic may have the potential to slow down ageing and enhance longevity. Originally developed for diabetes management, the drug semaglutide has gained immense popularity for its weight loss effects, prompting a surge in its use worldwide. Ozempic, along with its counterpart Wegovy, works by mimicking the action of the GLP-1 hormone, which regulates appetite and promotes a feeling of fullness.

While a growing trend has emerged online with individuals taking these drugs in small doses to pursue anti-ageing benefits, health experts caution that their effects in humans remain unverified. Researchers from the Chinese University of Hong Kong have provided some insight into this area. Their study focused on exenatide, a drug similar in chemical structure to Ozempic, and its potential to counteract ageing in mice.

Study Findings on Ageing in Mice

The research involved administering a low dose of exenatide to mice beginning at approximately 11 months of age, continuing for a duration of 30 weeks. Scientists collected tissue samples from various organs, including the brain, liver, kidneys, muscle, and adipose tissue. They evaluated changes in RNA and DNA modifications, along with several proteins and metabolism-related molecules, to assess the impact of the drug on the “age-signature” of each tissue.

The findings revealed that exenatide induced consistent changes across multiple tissues, counteracting typical ageing patterns. The treated mice exhibited metabolic health comparable to that of younger animals. Furthermore, their “age-signature” shifted significantly towards a “younger-looking” profile when compared to untreated older mice. Researchers noted that many of the drug’s beneficial effects appeared to be linked to brain activity, suggesting that the brain could play a pivotal role in influencing the ageing profiles of various organs.

Implications and Future Research

Despite these promising results, the researchers emphasized a critical limitation: the findings are based solely on mouse subjects, and the effects on human ageing remain unproven. The study focused on middle-aged mice, indicating the possibility that the drug’s efficacy may differ in older animals. While the research indicated potential molecular signs of younger age across tissues, it did not demonstrate actual reversal of ageing in the mice.

“Our work has provided multifaceted evidence for a comprehensive body-wide anti-aging strategy,” the researchers stated. They underscored the need for future longitudinal studies to explore whether GLP-1 receptor agonism, such as that seen with exenatide, could complement existing anti-ageing methods. As interest in the longevity benefits of weight loss drugs grows, this research could pave the way for larger clinical trials and the development of effective anti-aging treatments.